Resumen de acción SYNH
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Syneos Health, Inc.
Historial de precios y rendimiento
Historical stock prices | |
---|---|
Current Share Price | US$42.98 |
52 Week High | US$52.23 |
52 Week Low | US$22.89 |
Beta | 1.58 |
1 Month Change | 0.66% |
3 Month Change | 1.99% |
1 Year Change | -8.84% |
3 Year Change | -23.06% |
5 Year Change | -10.61% |
Change since IPO | 109.76% |
Noticias y actualizaciones recientes
Recent updates
Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?
Mar 29Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?
Mar 10Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?
Feb 20Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?
Dec 20Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?
Nov 28Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors
Nov 01Syneos, Datavant expand partnership on data analytics for clinical trials
Oct 11Syneos Health falls 13% after update on outlook
Sep 13When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?
Sep 08Is Syneos Health (NASDAQ:SYNH) A Risky Investment?
Aug 22Syneos Health Q2 2022 Earnings Preview
Aug 01With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case
Jul 19Syneos: Upside Could Be Priced In, Valuations Unsupportive
Jul 15Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?
Jun 18Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?
Jun 03We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt
May 19Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?
Apr 08Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors
Mar 27Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?
Mar 05Is Syneos Health (NASDAQ:SYNH) A Risky Investment?
Feb 18Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?
Feb 03With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting
Jan 04Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022
Dec 03Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?
Dec 03Rentabilidad de los accionistas
SYNH | US Life Sciences | Mercado US | |
---|---|---|---|
7D | 0.6% | -4.1% | -3.2% |
1Y | -8.8% | -6.7% | 19.3% |
Rentabilidad vs. Industria: SYNH superó al sector US Life Sciences , que obtuvo un rendimiento del -13.4% el año pasado.
Rentabilidad vs. Mercado: SYNH obtuvo unos resultados inferiores a los del mercado US, que fue del 14.1% el año pasado.
Volatilidad de los precios
SYNH volatility | |
---|---|
SYNH Average Weekly Movement | 0.3% |
Life Sciences Industry Average Movement | 7.0% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: SYNH no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: SYNHLa volatilidad semanal ha disminuido de 9% a 0% en el último año.
Acerca de la empresa
Fundada | Empleados | CEO | Página web |
---|---|---|---|
2010 | 28,768 | Michelle Keefe | www.syneoshealth.com |
Resumen de fundamentos de Syneos Health, Inc.
Estadísticas fundamentales de SYNH | |
---|---|
Capitalización bursátil | US$4.46b |
Beneficios(TTM) | US$71.22m |
Ingresos (TTM) | US$5.42b |
62.6x
Ratio precio-beneficio (PE)0.8x
Ratio precio-ventas (PS)¿Está SYNH sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
Cuenta de resultados (TTM) de SYNH | |
---|---|
Ingresos | US$5.42b |
Coste de los ingresos | US$4.22b |
Beneficio bruto | US$1.20b |
Otros gastos | US$1.13b |
Beneficios | US$71.22m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) | 0.69 |
Margen bruto | 22.14% |
Margen de beneficio neto | 1.31% |
Ratio deuda/patrimonio | 75.8% |
¿Cómo se ha desempeñado SYNH a largo plazo?
Ver rendimiento histórico y comparativa